presentation made by aagami during illinois science and technology park event

Realizing Possibilities, Together

Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com

India Lifesciences Industry: Landscape & Opportunities for IL Companies

© Aagami, Inc. 2016 | All rights reserved | www.aagami.com

Dinesh Jain, Founder CEO, Aagami Inc.


India – an Introduction

IN Life sciences Industry Snapshot

Major centers of Life sciences in India

Major Deals and Investments Involving Indian companies

India IPR Scenario

Business and Cultural Differences

Benefits of Partnering with Indian companies

Introduction of Aagami, Inc.

2

Table of Contents

Note : These are some of the deals which Aagami Market Research Team have sourced from Publicly available data and hence not exhaustive

© Aagami, Inc. 2016 | All rights reserved | www.aagami.com3

INDIA – An Economic Introduction

8000 year old civilization (even older than Egypt and Mesopotamia)

The 2nd most populous(with over 1.32 billion people), 7th largest (by area)

Indian economy is the world’s 3rd largest in PPP (Purchase Power Parity) and 7th

largest by nominal GDP .

The Indian economy would become the world's 3rd-largest economy by 2025

India also topped the World Bank’s growth outlook for 2015-16 growth of 7.6% in2015-16 and expected to grow 7.7-8.0% in 2016-17.

Total transaction value of M&A involving Indian companies stood at US$ 26.3billion with 930 deals in 2015. The total value of M&As involving Indian companiessurged nearly 63 per cent to ₹507 billion ($7.8 billion) in the first three months of2016.

Total private equity (PE) investments in India for 2015 reached a record high of₹1,267.5 billion (US$ 19.5 billion) through 159 deals, according to the PwCMoneyTree India report.

During FY 2015, India received the FDI equity inflow from USA of ₹228 billion(USD 3.51 billion). Commitment of US$42billion (2015-2017) from USAorganisations.

Source: Aagami Business and Market Research and Authoritative sources such as http://www.ibef.org/economy/foreign-direct-investment.aspx, See more at: http://www.ibef.org/economy/indian-economy-overview#sthash.InZGWgd8.dpuf

http://www.ibef.org/economy/foreign-direct-investment.aspx


Source: Indian Economy At a Glance". Retrieved 2015-10-09. https://principles-of-economics-and-business.blogspot.in/2015/09/indian-economy-at-glance.html, http://www.ibef.org/economy/indian-economy-overview#sthash.InZGWgd8.dpuf, IMF

Key Parameters Value Year

GDP ₹156 trillion (USD 2.40 trillion) 2016

GDP Growth 7.6% 2016

Inflation 5.39% May 2016

GDP per Capita (PPP) USD 5,900 2015

Foreign Direct Investment Inflow USD 63 billion 2015

Foreign Direct Investment outflow (Jan-Feb 2016)

₹ 325 billion (USD 5 billion) 2016

Global consumer confidence Index created by Nielsen

Rank #1 Dec 2015

Indian Economy at a Glance

Economic Growth Projections

India is placed among the top three countries with the most number of billionaires in the world.

India has 97 billionaires, and their combined wealth adds up to $266 billion.

4

https://principles-of-economics-and-business.blogspot.in/2015/09/indian-economy-at-glance.html

http://www.ibef.org/economy/indian-economy-overview#sthash.InZGWgd8.dpuf


India is the 3rd largest Pharma market by volume and 10th in terms of value

globally.

Every 3rd pill in the world, is Made in INDIA.

Largest Provider of Generic medicines Globally (20%)

Over 20,000 pharmaceuticals and biotech companies.

More than 550 US FDA Approved facilities, highest for any country outside the

US

India Pharma is expected to expand at a CAGR of 12.89%

to reach USD55 billion by 2020 (conservative

projection).

The drugs and pharma sector attracted cumulative FDI inflows worth ₹874.25 billion (US$ 13.45 billion) between April 2000 and

Dec2015

More than 60,000 distributors and about

800,000 pharmaceuticals retailers.*

Approval time for new facilities has been drastically

reduced.

Source: Dec 2015-India Brand Equity Foundation www.ibef.org; http://www.tradingeconomics.com/india/exports-of-pharmaceutical-products

Lifesciences Industry in India: Fast growing and Regulated – 1 of 2

5

http://www.inef.org/

http://www.tradingeconomics.com/india/exports-of-pharmaceutical-products


More than top 50 Indian companies have presence in

the regulated market (US, Canada, Western EU and

Japan).

More than 100 companies from India are present in 50+

countries.

Indian healthcare market is ₹6,500 billion (USD100

billion) (Dec 2015)

Healthcare sector is expected to reach ₹16,250 billion (USD 280 billion) by

2020.

Growing at a CAGR of 17%

The hospital and diagnostic centers attracted FDI worth

₹221.6 billion (US$ 3.41 billion) between April 2000

and Dec2015

Approx. 50% of the essential medicines that UNICEF distributes in emerging

countries come from India

Indian medical tourism is pegged at ₹195 billion (US$ 3

billion) per annum (Dec 2015)

Domestic formulation market stood at ₹685 billion

(US$ 10.54 billion)

India's filing of Drug Master Files (DMF's) with USFDA is

among the highest in the world.

Source: Dec 2015-India Brand Equity Foundation www.ibef.org; http://www.tradingeconomics.com/india/exports-of-pharmaceutical-products6

Lifesciences Industry in India: Fast growing and Regulated – 2 of 2

http://www.inef.org/

http://www.tradingeconomics.com/india/exports-of-pharmaceutical-products


Cost Efficiency• Low cost of production and R&D boosts efficiency of

Indian pharma companies

• India’s cost of production is approximately 60 per cent lower than that of the US and almost half of that of Europe

• Due to lower cost of treatment, India is emerging as a leading destination for medical tourism

Economic Drivers• Economic prosperity to improve drug affordability

• Increasing penetration of health insurance

• With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available

Diversified Portfolio• Accounts for over 10 per cent of the global

pharmaceutical production

• Over 60,000 generic brands across 60 therapeutic categories.

• Manufactures more than 500 different APIs

• 49 per cent of all drug master filings from India is registered in the USA

Policy Support• Government unveiled ‘Pharma Vision 2020’ aimed

at making India a global leader in end-to-end drug manufacturer

• Reduced approval time for new facilities to boost investments

• 100 per cent FDI is allowed under automatic route

India Pharma

INDIA PHARMA – Key Features

Source: IBEF Pharma Report Jan 2016

Parameters Total cost in %

Cost in US 100%

Production cost in India

50%

R&D cost in India 30%

Clinical trial cost in India

40%

Relative Cost advantage in India(%) [Thumb Rule]

7


India Pharma by Type of Drugs and Therapy Areas

Source: IBEF Pharma Report Jan 20168


Notable Trends from India Pharma

R&D

• Indian companies spend 8-11 % of their total revenue on R&D

• Expenditure on R&D has increased due to the introduction of product patents; companies are developing new technologies and drugs to boost sales

Export Revenue

• India’s pharmaceutical export market is thriving due to strong presence in the generics space

• Pharma exports reached USD15 billion in 2015 and estimated to reach USD18.02 billion in 2016

Joint Ventures

• Multinational companies are collaborating with Indian pharma firms to develop new drugs

Global Expansion by Indian companies

• Indian companies are expanding globally by mergers, acquisitions, and other partnerships.

• Indian companies are not only cash rich but also hungry to compete with the Best of the West

Less Time for Approval

• In order to compete with global players in pharmaceutical industries, approval process of drugs have been simplified by the authorities and approval time for new facilities has been drastically reduced

9


Majority of Indian states host Life Science business centres in India (1/2)

City Major Companies

Mumbai Sun Pharma, Lupin, Wockhardt, Glenmark, USV, Ipca, Indoco Remedies, Bharat Serum and Vaccines Ltd, Cipla, FDC, Most MNCs

Ahmedabad Zydus, Cadila, Intas, Torrent, Dishman, Helios, Claris Lifesciences

Hyderabad Dr.Reddy’s, Aurobindo, Suven LifeSciences, Divi’s, Hetero, Shantha Biotech, Granules India, Natco Pharma, GVK Biosciences

Bengaluru Biocon, Micro, Strides, GSK,Advinus, AstraZeneca, Aurigene, Avesthagen, Bal Pharma, Biozeen, Bayir Group, Bhat Bio-tech, Camson Bio technologies, Global Calcium, Indigene Life system

New Delhi Ranbaxy, Panacea, Jubilant Life Sciences, Advanced Life Sciences, Akum Drugs & Pharma, Dr. Lal Path Labs, JagsonPal Pharma, Life Medicare & Biotech, Mankind Pharma, Medicamen Biotech, ModiMundi Pharma, More pen, Nestor Pharma, Ozone Pharma & Ayurvedic

Chennai Orchid, Shashun, Tablets India, TTK Healthcare, Amrutanjan Health care, Arvind Remedies, Axon Drugs, Bafna, Caplin Point Labs, Cholayil, Fourrts India Labs, Life Cell International, Malladi Drugs & Pharma, Medopharm, Nutra Specialities

Pune Bilcare, Serum India, Advinus Emcure, Acoris Research, Hindustan Antibiotics, National Chemical Lab, Vlife Sciences

Navi Mumbai Reliance Life Science, Pfizer India, Wanbury, Alkem Pharma, Lilac Medicare, Thyrocare Technologies

Source: IndiaBioscience.org

The Indian Diverse geography caters to many Life Science business centres in India

10


City Major Companies

Chandigarh Surya Pharma, Nectar Life Sciences, Ind-Swift Labs

Vishakhapatnam Falcon Biotech, Vijaynagar Biotech Ltd, Actimus Biosciences Pvt.Ltd, Eisai Pharmatechnolgy Ltd, Techno med systems

Baroda Alembic Pharma, Ambrosia Ltd, Divine Laboratories, Hindustan Biosynth Ltd, Sterling Biotech Unicure Remedies

Noida & Gurgaon Ranbaxy Labs, Jubilant Life Sciences

Thane Aarti Drugs, Calyx Chemicals & Pharmaceuticals Ltd, Kremoint Pharma, Herbert Brown Pharmaceuticals & Research

Kolkata Adinath Bio-Labs, Allister Biotech, Krish Biotech, Allen India Ltd, Albert David Ltd, East India Pharmaceuticals Works, Emami, TCG Lifesciences

Indore Alpa Laboratories, Syncom Healthcare, Biofil Chemicals & Pharmaceuticals Ltd, Cyano Pharma, Parenteral Drugs India Ltd

Source: IndiaBioscience.org

The Indian Diverse geography caters to many Life Science business centres in India

Majority of Indian states host Life Science business centres in India (2/2)

11


City Centres

New Delhi All India Institute of Medical Sciences, Institute of Genomics and Integrative Biology, (IGIB)National Institute of Immunology, Institute of Cytology and Preventive Oncology (ICPO)

International Centre for Genetic Engineering & Biotechnology (ICGEB) Jawaharlal Nehru UniversityTERI University, Nizam's Institute of Medical Sciences

Bengaluru National Centre for Biological Science (NCBS) , National Institute of Mental Health and NeurosciencesStem Cell Institute

University of Agricultural Sciences, Jawaharlal Nehru Centre for Advanced Scientific Research, Indian Institute of Science (IISc)

Hyderabad Ashoka Trust for Ecology and the Environment International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) Centre for Cellular and Molecular Biology (CCMB)

LV PRASAD EYE INSTITUTE National Institute for NutritionIndian Institute of Chemical Technology

Pune Agarkar Research InstituteIndian Institute of Science Education and ResearchNational Chemical Laboratory (NCL) National AIDS Research Institute (NARI)

,National Institute of Virology (NIV),Microbial Containment ComplexThe National Centre for Cell Sciences

Mumbai Advanced Centre for TreatmentResearch and Education in CancerBhabha Atomic Research Centre (BARC)Bombay Natural History Society

Indian Institute of Technology Bombay (IIT- Bombay)Tata Institute of Fundamental Research (TIFR) University of Mumbai

Ahmedabad National Institute of Pharmaceutical Education and Research (NIPER)National Institute of Occupational Health (NIOH)

The Gujarat Cancer & Research InstituteInstitute for Plasma ResearchIndian Institute of Management Ahmedabad (IIM-A)

India has active Public and Private Institutes focused on research covering spectrum of Lifesciences (1/2) (Few centers listed below)

12


City Centres

Kolkata Bose InstituteIndian Institute of Chemical BiologyIndian Statistical InstituteJadavpur UniversityUniversity of Calcutta

Indian Institute of Science Education and ResearchCalcutta Medical Research InstituteMarine Engineering & Research Institute Indian Institute of Management (IIM- C)

Nagpur Central Institute for Cotton ResearchNational Research Centre for Citrus (NRCC)Indian Bureau of MinesNational Bureau of Soil Survey and Land Use Planning

National Environmental Engineering Research Institute (NEERI)National Institute of Intellectual Property Management (NIIPM)

Lucknow Birbal Sahni Institute of PalaeobotanyCentral Drug Research InstituteNational Botanical Research Institute

Industrial Toxicology Research Centre (ITRC)Indian Institute of Sugarcane Research (IISR)

Chennai Indian Institute of Technology MadrasUniversity of MadrasNational Institute for Research in Tuberculosis

The National Institute of Epidemiology (NIE)CENTRAL LEATHER RESEARCH INSTITUTE (CLRI)

India has active Public and Private Institutes focused on research covering spectrum of Lifesciences (2/2) (Few centers listed below)

13


India Co. USA Co.Deal Size (USD Mn)

Year Remarks

Wipro Health plan 460 2016HealthPlan Services is a Leading Technology and Business Process as a Service Provider in the US Health Insurance Market

Strides J&J N/A 2016 received CCI approval to acquire 7 brands from Johnson and Johnson

SRF Dupont 20 .0 2015 Pharma propellant business

Lupin Gavis 880 2015 Expand US generic

Torrent Pharma Zyg Pharma N/A 2015 Expand derma business in US

CiplaInvaGen Pharma & Exelan Pharma

550 2015 To boost its US business

Sun Pharma InSite Vision Inc 50 2015The acquisition was completed by means of a short-form merger under the Delaware law

Piramal OPIL & MSD BV 15 2015 acquisition of five trademark rights for India

PiramalColdstream Laboratories

30.65 2015 Injectable market segment

Aurobindo Natrol Inc. 132.5 2014 Nutraceuticals platform for US & ROW

Sun Pharma Pharmalucence N/A 2014 Radio- pharmaceuticals and US injectable business

Kemwell Cirrus N/A 2013 Products with faster time-to-clinic and cost savings for customers


US CompaniesIndian

CompaniesDeal Size (USD

Mn)Year Remarks

Mylan Famy Care 800 2015 Global women's health care

Quantum solutions

Parexel N/A 2015Create greater scale in service area, and provide comprehensive and efficient solution to global clients.

Hospira Orchid Pharma 200 2014 API supplier for key antibiotics and future API development.

Carlyle Group Bharat Serum 83 2014 25-30% stake from existing investors.

Amneal Pharma Epsilon Pharma 16 2014Expand footprint in India. Includes 200,000 + sf. US FDA certified manufacturing facility.

Mylan Agila 1,600 2013 Become top-three global player in injectable

India Co. USA Co. Year Remarks

Ami Organics Photolitec 2015 Clinical trials to determine cancer treatments safety and and efficacy.

Emami Hevert-Arzneimittel 2014Launched products via 400 homoeopathy medicine retail outlets across diverse distribution channels via Emami.

Agila Biotech Pfenex Inc 2013Develop, manufacture and commercialize initial pipeline of 6 biosimilar products. AB = 51% equity stakeholder

USA - India – Joint Ventures


USA CompaniesIndia Companies

Year Remarks

Lab Pisa Biocon 2016 co-development & commercialization agreement for rh- Insulin in USA

BioQ Pharm Cipla 2016 agreement to commercialize BioQ's Ropivacaine Infusion System in India

Cyclopharm Jubilant 2015Jubilant's subsidiary DraxImage signs pact with Cyclopharm to market Technegas in US. DraxImage will provide up to $4.5M USD to fund the USFDA clinical trial , and also pay 17.5% royalty.

Golden Helix MedGenome 2015 better tailor diagnostic and therapeutic strategies to individual patients.

Phyto Biotech Hysun Inc 2015 Hysun Inc forays into India market through partnership with India based Phyto Biotech

Oncobiologics Ipca Labs 2014 Development, manufacture and commercialization of biosimilar monoclonal antibodies.

BioQuiddity Cipla 2014Commercial collaboration on OneDose ReadyfusOR™ in anaesthetic applications for post-surgical pain management.

Endo Pharma GVK Bio 2013Novel small molecules. GVK BIO will use discovery expertise and Endo will develop/commercialize product.

Moffitt Cancer Centre

Advinus 2013 New oncology therapies.

Onconova Therapeutics GVK Bio 2013 US JV to move Onconova oncology assets from early discovery to clinical development stage.

Novavax Cadila 2013 Extension to JV in 2009 collaboration to develop novel malaria vaccine in India.


USA Companies India Companies Year Remarks

Fidelity Growth MedWell Ventures 2015Fidelity Growth Partners invest USD 10 Mn in India based Medwell Ventures, with plans to expand rapidly across the country

US MarketGlenmark 2014 Greenfield facility for US market for USD 100 Mn

Chase PharmaCipla 2014 Alzheimer’s drug development. Part of $21 M investment through syndicate

Oncobiologics Strides 2014 Strategic stake

US Market Lupin 20142 new US R&D Centres on inhalation and complex formulations research for USD 177.5 Mn

During FY 2015, India received the FDI equity inflow from USA of ₹228 billion(USD 3.51 billion). Commitment of US$42billion (2015-2017) from USAorganisations.

US – INDIA - Foreign Direct Investments


USA Co. India Co. Year Remarks

Xenoport Dr. Reddy’s 2016enters US licensing agreement for development and commercialization of a clinical-stage oral new chemical entity

Natera MedGenome 2015 Exclusive license to develop Natera's Panorama.

GileadStrides Arcolabs

2015Non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF); license extends to 112 countries

Gilead Natco India 2015 Generic versions of chronic hepatitis C medicines.

Visterra Serum 2015license agreement for a humanized monoclonal antibody.Deal value approx. USD 40 million excluding royalties

Fresenius Kabi Caplin Point 2015Caplin Point receive milestone payments for licensing agreements with Fresenius Kabi USA, and Cycle Pharma, UK

Taxus Cardium Dr. Reddy’s 2015 Announces licensing agreement

Epirus Ranbaxy 2014 Infliximab (arthritis) with annual sales of $6 billion..

Merck Sun Pharma 2014 Worldwide rights to tildrakizumab. $ 280 M Deal

Cytosorbents Biocon 2014Distribute CytoSorb® for critical care applications in ICU and cardiac surgery applications for India and select emerging countries.

India from USA – Licensing deals


The Evolution Of India’s Patent Law

India’s Approach To Patentability Standards

Compulsory Licensing

Patent Linkage And Data Exclusivity

Pharma Economics In The Rich And Lesser Rich Worlds

Emerging Challenges

The Road Ahead

INDIA- IPR Regime (ref: India IPR Report Aug 2015)

19


The time limit given for submitting the application for grant has been reduced to 4 months from 12 months, providing an extension of 2 months

Necessary permissions to be taken from the concerned authority before the grant of patents

The introduction of product patents in India in 2005 gave a boost to the discovery of new drugs

India reiterated its commitment to IP protection following the introduction of product patents

INDIA- Draft Patents (Amendment) Rules, 2015

20


India's stance is that the current patent regime is fully TRIPs compliant, striking the appropriate balance between the grant of monopoly patent rights and public health imperatives

IPA presented data to suggest that the gulf between US and Indian patent regimes may not be as wide as perceived in terms of outcomes for patentees.

Several collaboration deals between US firms and domestic companies including,

Amgen - Dr Reddy's to distribute Amgen's oncology and cardiology medicines,

Gilead's licensing agreement with companies for hep C generic medicines,

Merck and Sun Pharma for tildrakizumab, and Boehringer Ingelheim India with Lupin for linagliptin,

INDIA-Strengthening the Patent Office

Supreme Court has interpreted the Patents Act to remove apprehensions of abusive multiplicity of challenges to the validity of a patent

Important legislation is now in place to speed up resolution of commercial disputes, including those relating to intellectual property rights.

Some long-standing substantive grievances of US companies relating to India's IPR regime remain.

Mainly compulsory licensing provision, prohibition on grant of patents to new forms of known substances without therapeutic benefit.

US innovator companies are also concerned by the alleged lack of data exclusivity.

Specific steps have already been taken; MNCs are collaborating with companies in several ways above to increase access in the Indian market.

Souce: http://timesofindia.indiatimes.com/business/india-business/US-pharma-body-slams-Indian-patent-regime/articleshow/50908408.cms>

21


Many US-based companies, are trying to evergreen their patents through cosmetic changes, and applying for fresh patents. But they have been largely unsuccessful in India

http://www.autonews.com/apps/pbcs.dll/article?AID=/20030616/SUB/306160708/landmark-patent-case-broke-seldens-lock-on-auto-industry

A special provision in the Indian Patents Act, Section 3 (d), allows the Indian Patents Controller to

Deny patents on items that are not significantly different from their older versions.

Low cost generic medicines manufactured in India have been making medical care affordable for millions in Africa and Latin America, not to mention the US itself.

“Criticism of India’s IPR regime is best ignored”

The powerful US pharmaceutical lobby has a problem with Indian pharma producers, who have managed to serve the poor not just in India but across the world.

It also does not want compulsory licenses to be issued for manufacture of copies of patented drugs to address situations of national emergency, as permitted by the TRIPS agreement.

Placed in the ‘priority watch’ list of countries that (according to the US)need to tighten their IP laws.

Through its Special 301 report, the US is trying to push India to drop Section 3 (d).

With the multilateral trade laws on India’s side and the interest of millions of poor, USTR’s efforts should be ignored or laughed off

Source: http://www.thehindubusinessline.com/opinion/columns/us-on-its-own-trip/article8576022.ece22

http://www.autonews.com/apps/pbcs.dll/article?AID=/20030616/SUB/306160708/landmark-patent-case-broke-seldens-lock-on-auto-industry


Business Cultural Differences sample

Meanings of Phrases and points in the US vs IN

As Soon as Possible: ASAP vs ASAP

Tomorrow: Next day vs In near future

Will be done: surely be done vs will try best

Business focus: Specialist vs Generalist

Work driven by: Process vs Ad Hoc

Everyday working: MBO vs MBC

Business Transaction: Contractual vs Trust base

Importance: Transaction vs Relationship

Relationship: Short Term vs Long Term


Benefits to companies Collaborating with Indian Companies

Source: India Pharma Inc. Enhancing value through alliances and Partnerships – Pharma Summit- 2011(PwC & CII Report)

Pharma MNCs collaborating with Indian companies bring to table new products, latest technology, higher investments, quality systems and the knowledge of regulatory process

On their part, Indian companies provide local market knowledge, cost advantage and local scientific talents.

Such alliances have the potential to bring significant benefits to both parties and value to society as a whole. Such partnership bring in new drugs and therapies to the market and increase patient's awareness about diseases and wider treatment choices available

>> Lilly is currently transforming itself from a traditional fully integrated pharmaceutical company into a fully integrated pharmaceutical network, so that it can draw on a range of resources beyond its own walls.

>> Lilly hopes teaming up with the other organization to create virtual R&D programmes will enable it to get better access innovation, reduce costs, manage risks more efficiently and enhance productivity. For example, the Chorus project is a virtual organization to take molecules quickly to proof of concept.

>> Lilly also uses external networks comprising third parties such as Piramal Life Science, Hutchinson MediPharma, and Suven Life Science in the development of molecules

Enhancing value through alliances and Partnerships



Aagami, Inc.

A life sciences consulting firm based in the suburbs of Chicago offers services in

For Global Biotech, Pharmaceutical , Medical Devices, Consumer Health products companies, Universities, in their initiatives with US, India, Asia, Brazil, Latin America and Emerging Markets.

Strategic ConsultingTechnology Licensing Market Intelligence


Strategic Consulting Services

In-Licensing

Out-Licensing

Co-Development and Partnerships

Investments to and from US/India/Asia/Brazil/Latin America

Mergers & Acquisitions

Finding the Right Partners

JV and/or Distributors/ Contract Sales/Marketing/Contract Manufacturing, CRO and CRAMS providers

New Market Entry Strategy/ Development


Aagami brings

Deep Understanding of business and socio-cultural differences in ways of working.

Extensive network with Top LifeSciences companies at C levels

Global Deal experience.

Aagami Partners bring value of combined experience of over 150 years.

Focus on client needs, objectives, success and work as an extension of client’s own team.

28

InternationalPhosphagenics Australia

PeptiSyntha Belgium

DelMar Pharma Canada

Affitech Denmark

Pieris Germany

Merus Holland

Venus Remedies India

Opsona Ireland

Toppan Japan

Otago University New Zealand

Aagami has completed over 100 assignments for more than 60 clients in the last 13+ years.

United States

Advangene IL

Loyola Univ. Chicago IL

Dow Chemicals MI

ScyFIX MN

OncBioMune LA

Penwest Corp. NY

DesignMedix OR

PLx TX

CreAgri CA

New Heaven Pharma CT

Sample list of Aagami Clients


Sample of Aagami Connectivity in India

We have a working relationship at C Level of TOP 100 Lifesciences companies in India. Some of the popular names are below.

Biocon Intas Sun Pharma

Cadila Lupin Themis

Cipla MicroLabs Torrent Pharma

Dr Reddys Piramal USV

Glenmark Reliance Wockhardt

Hetero Drugs Strides Zydus


USA (Head Office)

Aagami, Inc. 2135 City Gate Lane Suite 300

Naperville, IL 60653

P: +1-630-364-1837

INDIA

Aagami

741, Nelson Square

Nagpur – 440013

P: +91-712-258-6678

Dinesh Jain

Email: [email protected]

M: +1 630-853-3520

Godwyn Francis

Email: [email protected]

M: +91-787-501-6957

www.aagami.com

30Realizing Possibilities, Together

CONTACT US

mailto:[email protected]

mailto:[email protected]

http://www.aagami.com/